Company Profile
ClearPoint Neuro Stock Price, News & Analysis
Company overview
Business overview
ClearPoint Neuro is a biopharmaceutical company focused on advancing a pipeline of therapeutic programs. Investors usually track how clinical data, regulatory milestones, and launch execution change the story over time.
Geographic Base and Sector Classification
Headquartered in the United States and listed on NASDAQ, ClearPoint Neuro is followed within the biotech universe for its exposure to catalyst-driven execution.
Business Model Characteristics
ClearPoint Neuro follows a catalyst-driven model where the market watches how the company turns development work into repeatable value creation.
Position Within the Biotechnology Landscape
Compared with more mature healthcare peers, ClearPoint Neuro sits closer to the development side of the biotechnology landscape, where timing around data and approvals matters most.
Why the stock is moving
CLPT is trading with a steady catalyst profile while investors wait for the next headline that changes the story.
Future catalysts
ClearPoint Neuro’s catalysts are neurosurgical-navigation adoption, clinical workflow growth, and any platform expansion into more procedures. The company improves when the installed base becomes more recurring.
Recent news
The five most recent feed items are shown below in reverse chronological order.
- 01
ClearPoint Neuro Announces Agreement to Acquire IRRAS
Source: ClearPoint Neuro
- 02
ClearPoint Neuro Reports Third Quarter 2025 Results
Source: ClearPoint Neuro
- 03
ClearPoint Neuro Completes Acquisition of IRRAS
Source: ClearPoint Neuro
- 04
ClearPoint Neuro Announces Preliminary Unaudited Fourth Quarter and Full Year 2025 Revenue
Source: ClearPoint Neuro
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.